Podcast | From Tariffs to Trade Deals: What the UK–US Pharma Agreement Means
· Posted on: December 22nd 2025 · read
The UK and US have signed a landmark agreement that could reshape the pharmaceutical and life sciences landscape for decades to come.
In this episode of our Life Sciences podcast, Yogan Patel, Head of Life Sciences, Pharma & MedTech at MHA, is joined by Brendan Murphy, Partner at Baker Tilly Ireland, and Andrew Thurston, Customs Manager at MHA. Together, they explore the potential impact of this UK–US pharma agreement and President Trump’s recent tariff announcements on the sector.
With rumours that tariffs could reach unprecedented levels, global supply chains and pharmaceutical production face significant disruption.
Our experts break down:
- What the agreement means for businesses on both sides of the Atlantic.
- How companies are adapting to the changing trade environment.
- Whether this marks the start of a new era for pharma or just the calm before the next storm.
Listen now
Discover our previous podcast

Yogan A. Patel

Brendan Murphy

Andrew Thurston
Ready to Talk?
Get expert advice on navigating trade changes and supply chain challenges.
Discover more insights
Podcast | Tariffs, Trump, and the Future of Pharma
Unlocking biotech potential: What the US–UK tech partnership means for drug discovery
Yogan A. Patel
Head of Life Sciences & MedTech
Pharmaceutical Pricing: What Europe Must Do to Ensure Affordability and Patients Access to Drugs
Yogan A. Patel
Head of Life Sciences & MedTech
Patent Box: The Long-Term Tax Advantage for IP-Driven Startups
Kanika Mishra Pathak
Lead R&D Director